PageOverview.com
 

Websites, domains, hosts that links to azpicentral.com

Our database shows, that the website azpicentral.com is linked by a total of 32 websites.

 
Number of websites/domains displayed: 32
Results found: 32
 

Websites discovered:

TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) | HCP Site
http://pageoverview.com/website-report/tudorzahcp.com
Healthcare professional information on TUDORZA PRESSAIR (aclidinium bromide inhalation powder), an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with COPD.
  • Expected expiration: May 10th in 2020
  • Creation date: May 10th in 2012
  • Renew date: March 24th in 2016
BEVESPI AEROSPHERE® (glycopyrrolate/formoterol fumarate) Inhalation Aerosol
http://pageoverview.com/website-report/bevespi.com
BEVESPI AEROSPHERE is a twice-daily long term treatment for adults with COPD.
  • Expected expiration: October 2nd in 2018
  • Creation date: October 2nd in 2014
  • Renew date: September 28th in 2017
BRILINTA® (ticagrelor) tablets | Health Care Professional Web site
http://pageoverview.com/website-report/brilintatouchpoints.com
  • Expected expiration: October 15th in 2017
  • Creation date: October 15th in 2009
  • Renew date: October 11th in 2016
Official Website for BYDUREON® (exenatide extended-release for injectable suspension)
http://pageoverview.com/website-report/bydureon.com
Learn about BYDUREON® (exenatide extended-release for injectable suspension), a non-insulin treatment option for adults with type 2 diabetes available in the BYDUREON Pen.
  • Expected expiration: November 15th in 2022
  • Creation date: November 15th in 2007
  • Renew date: January 29th in 2016
ONGLYZA® (saxagliptin) | Adult Type 2 Diabetes Medication
http://pageoverview.com/website-report/onglyza.com
Read information about ONGLYZA® (saxagliptin), an adult type 2 diabetes medication used with diet and exercise to help reduce A1C levels.
  • Expected expiration: January 19th in 2019
  • Creation date: January 19th in 2006
  • Renew date: January 15th in 2018
FASENRA™ (benralizumab) - Treatment Option for Eosinophilic Asthma | for HCPs
http://pageoverview.com/website-report/fasenrahcp.com
Learn more about the now-approved FASENRA for add-on treatment of eosinophilic asthma.
  • Expected expiration: May 23rd in 2018
  • Creation date: May 23rd in 2017
  • Renew date: September 13th in 2017
Immunotherapy for Advanced Bladder Cancer | For Patients | IMFINZI™ (durvalumab)
http://pageoverview.com/website-report/imfinzi.com
IMFINZI™ (durvalumab) is an immunotherapy used to treat a type of cancer in the bladder and urinary tract called urothelial carcinoma. Learn more about IMFINZI.
  • Expected expiration: April 30th in 2018
  • Creation date: April 30th in 2015
  • Renew date: April 26th in 2017
PI-Central
http://pageoverview.com/website-report/azpicentral.com
  • Expected expiration: July 8th in 2017
  • Creation date: July 8th in 2014
  • Renew date: January 29th in 2016
MOVANTIK® (naloxegol) | Opioid Induced Constipation Treatment
http://pageoverview.com/website-report/movantik.com
Official Web site for MOVANTIK® (naloxegol) tablets, for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
  • Expected expiration: September 25th in 2017
  • Creation date: September 25th in 2013
  • Renew date: September 20th in 2016
Official Website for BYDUREON® (exenatide extended-release) for injectable suspension
http://pageoverview.com/website-report/bydureonfin15.com
Learn about BYDUREON, a non-insulin treatment option for adults with type 2 diabetes available in the BYDUREON Pen.
  • Expected expiration: December 19th in 2017
  • Creation date: December 19th in 2014
  • Renew date: June 14th in 2017
Acid Reflux Medication | NEXIUM® (esomeprazole magnesium)
http://pageoverview.com/website-report/purplepill.com
Discover NEXIUM, the Purple Pill, which offers 24-hour heartburn relief caused by acid reflux disease. Ask your doctor if NEXIUM may be right for you.
  • Expected expiration: October 29th in 2017
  • Creation date: October 29th in 1999
  • Renew date: October 25th in 2016
Official BYDUREON® (exenatide extended-release for injectable suspension) Healthcare Professional Website
http://pageoverview.com/website-report/bydureonhcp.com
Learn about once-weekly BYDUREON, the BYDUREON Pen, and how BYDUREON affected A1C levels and more in multiple clinical trials.
  • Expected expiration: February 19th in 2022
  • Creation date: February 19th in 2010
  • Renew date: January 29th in 2016
BRILINTA® (ticagrelor) tablets | Heart Attack Treatment
http://pageoverview.com/website-report/brilinta.com
Read about BRILINTA® (ticagrelor) tablets, a prescription medication for heart attack treatment, or severe chest pain, also known as unstable angina.
  • Expected expiration: April 21st in 2018
  • Creation date: April 21st in 2005
  • Renew date: April 17th in 2017
BEVESPI AEROSPHERE® (glycopyrrolate/ formoterol fumarate) Inhalation Aerosol
http://pageoverview.com/website-report/bevespiaerosphere.com
BEVESPI AEROSPHERE® (glycopyrrolate/ formoterol fumarate) is a long‐term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
  • Expected expiration: August 13th in 2018
  • Creation date: August 13th in 2015
  • Renew date: August 9th in 2017
SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol | Asthma & COPD Medicine
http://pageoverview.com/website-report/mysymbicort.com
Official patient Web site for SYMBICORT, a medicine for the treatment of asthma and COPD. Find information about the inhaler and side effects
  • Expected expiration: July 25th in 2017
  • Creation date: July 25th in 2006
  • Renew date: July 21st in 2016
FARXIGA® (dapagliflozin) | Type 2 Diabetes Medication for Adults
http://pageoverview.com/website-report/farxiga.com
FARXIGA® (dapagliflozin) is an adult type 2 diabetes medication used with diet and exercise to improve glycemic control.
  • Expected expiration: August 27th in 2017
  • Creation date: August 27th in 2013
  • Renew date: August 23rd in 2016
P&T Community |
http://pageoverview.com/website-report/ptcommunity.com
  • Expected expiration: May 20th in 2017
  • Creation date: May 20th in 2002
  • Renew date: July 22nd in 2015
  • Google Analytics: 2492160-1
MOVANTIK® (naloxegol) | Mu-Opioid Receptor Antagonist
http://pageoverview.com/website-report/movantikhcp.com
Official health care professional Web site for MOVANTIK® (naloxegol) tablets, for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
  • Expected expiration: February 14th in 2019
  • Creation date: February 14th in 2014
  • Renew date: January 29th in 2016
Bipolar Disorder Medication | SEROQUEL XR® (quetiapine fumarate)
http://pageoverview.com/website-report/seroquelxr.com
Find information to better understand major depressive disorder (MDD), bipolar disorder, bipolar depression, and SEROQUEL XR® (quetiapine fumarate).
  • Expected expiration: March 29th in 2018
  • Creation date: March 29th in 2007
  • Renew date: March 25th in 2017
Official Website for BYDUREON® (exenatide extended-release) for injectable suspension
http://pageoverview.com/website-report/bydureonrhy15.com
Learn about BYDUREON, a non-insulin treatment option for adults with type 2 diabetes available in the BYDUREON Pen.
  • Expected expiration: December 19th in 2017
  • Creation date: December 19th in 2014
  • Renew date: June 14th in 2017
FASENRA™ (benralizumab) Subcutaneous Injection 30 mg
http://pageoverview.com/website-report/fasenra.com
FASENRA™ (benralizumab) is a prescription medicine used with other asthma medicines for the maintenance treatment of asthma in adults whose asthma is not controlled with their current asthma medicines.
  • Expected expiration: August 1st in 2018
  • Creation date: August 1st in 2016
  • Renew date: September 13th in 2017
PARP inhibitor for Advanced Ovarian Cancer | LYNPARZA® (olaparib)
http://pageoverview.com/website-report/lynparzahcp.com
LYNPARZA® (olaparib) is the first and only PARP inhibitor approved in 2 distinct settings: maintenance for recurrent ovarian cancer and following 3 or more lines of prior chemotherapy.
  • Expected expiration: December 4th in 2018
  • Creation date: December 4th in 2014
  • Renew date: November 30th in 2017
SYNAGIS® (palivizumab) Parent & Caregiver Website
http://pageoverview.com/website-report/synagis.com
Parent and caregiver information for SYNAGIS, a therapy to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in children at high risk for severe lung disease from RSV.
  • Expected expiration: September 8th in 2018
  • Creation date: September 9th in 1998
  • Renew date: September 4th in 2017
LYNPARZA® (olaparib) | Ovarian Cancer Treatment
http://pageoverview.com/website-report/lynparza.com
LYNPARZA®(olaparib) is a type of targeted therapy for ovarian cancer called a PARP inhibitor. LYNPARZA may be used at different stages of ovarian cancer treatment.
  • Expected expiration: February 10th in 2019
  • Creation date: February 10th in 2014
  • Renew date: January 29th in 2016
SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol For Health Care Professionals
http://pageoverview.com/website-report/symbicorttouchpoints.com
Official HCP site for SYMBICORT, an asthma and COPD treatment, providing information on the inhaler, side effects, dosage and prescribing information.
  • Expected expiration: October 15th in 2017
  • Creation date: October 15th in 2009
  • Renew date: October 11th in 2016
FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) | Flu Vaccine
http://pageoverview.com/website-report/flumistquadrivalent.com
Help protect against seasonal flu with FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) - the flu vaccine that starts working in the nose.
  • Expected expiration: December 6th in 2017
  • Creation date: December 6th in 2011
  • Renew date: December 2nd in 2016
Type 2 Diabetes Medication | BYETTA® (exenatide) injection
http://pageoverview.com/website-report/byetta.com
BYETTA is a non-insulin type 2 diabetes injection medication for adults.
  • Expected expiration: February 3rd in 2018
  • Creation date: February 3rd in 2004
  • Renew date: January 29th in 2017
FARXIGA® (dapagliflozin) | Treatment for Type 2 Diabetes Mellitus in Adults
http://pageoverview.com/website-report/farxiga-hcp.com
FARXIGA® (dapagliflozin) is an SGLT2 inhibitor indicated for patients with type 2 diabetes mellitus. Explore the science behind FARXIGA.
  • Expected expiration: September 23rd in 2017
  • Creation date: September 23rd in 2013
  • Renew date: September 19th in 2016
IRESSA® (gefitinib) Treatment
http://pageoverview.com/website-report/iressa-usa.com
IRESSA® (gefitinib) is a treatment for patients.
  • Expected expiration: June 8th in 2018
  • Creation date: June 8th in 2015
  • Renew date: June 4th in 2017
BreathABLETM | SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol
http://pageoverview.com/website-report/mybreathable.com
BreathABLE from SYMBICORT (budesonide/formoterol fumarate dihydrate) was created to help you control and manage difficulty breathing if you have COPD.
  • Expected expiration: September 8th in 2017
  • Creation date: September 8th in 2015
  • Renew date: September 7th in 2016
Type 2 Diabetes Treatment | QTERN® (dapagliflozin and saxagliptin) - For HCPs
http://pageoverview.com/website-report/qtern-hcp.com
Find out more about QTERN® (dapagliflozin and saxagliptin) and how it may help your patients in managing type 2 diabetes.
  • Expected expiration: March 17th in 2018
  • Creation date: March 17th in 2015
  • Renew date: March 13th in 2017
Official Website for BYDUREON® (exenatide extended-release) for injectable suspension
http://pageoverview.com/website-report/bydureonbybyby.com
Learn about BYDUREON, a non-insulin treatment option for adults with type 2 diabetes available in the BYDUREON Pen.
  • Expected expiration: February 25th in 2018
  • Creation date: February 25th in 2015
  • Renew date: June 14th in 2017
0.0332 // 2024-05-06 06:12:03
All Rights reserved 2018 © PageOverview.com